Why It’s Time to Re-evaluate Your Old Fill/Finish CDMO
Changing fill/finish CDMO With the costs to produce and package a drug climbing, companies are justifiably risk averse when it comes to changing fill/finish CDMOs.
Category: Drug Product Manufacturing
Don’t Miss the Opportunity – Increase in Diagnostics Manufacturing Demand
Message from Argonaut CEO Wayne Woodard – Global Increase in Diagnostics Manufacturing Demand I hope you are doing well and staying healthy in this challenging
Ensuring Access to Life-Saving Vaccine & Therapeutic Fill Finish Production
Immediate COVID-19 Vaccine & Therapeutic Fill Finish Production Availability Announced by Argonaut Manufacturing Services Advanced Facility Readies to Combat COVID-19 (Carlsbad, CA) March 23, 2020
Need for Pharmaceutical and Diagnostics Surge Capacity Revealed by the Coronavirus Outbreak
The pandemic revealed need for pharmaceutical and diagnostics surge capacity The global COVID-19 outbreak has served as an important lesson for companies worldwide on the
Argonaut Proudly Hosting BIO International Ecosystem Tour in San Diego
Open Biopharma and Argonaut Manufacturing Services selected to host BIO International Ecosystem Tour in North County, San Diego CARLSBAD, CA, Mar. 3, 2020 Open Biopharma
Argonaut Manufacturing Services and Particle Measuring Systems Partnering for Top Tier Results
Providing customers with high standards – Particle Measuring Systems (PMS) and Argonaut Manufacturing Services partnering Partnership leverages their individual strengths to achieve high quality, reliable
Argonaut Manufacturing Services announces launch of aseptic drug product manufacturing services
Argonaut Manufacturing Services announces launch of aseptic drug product manufacturing services New introduction supports industry shortage of high-yield filling service providers CARLSBAD, CA – Argonaut
How to Minimize API Loss: A Case Study in Aseptic Fill/Finish
With API (active pharmaceutical ingredient) values continuing to climb as production scales conversely drop, it is time to rethink our aseptic filling processes to minimize
The Make Versus Buy Dilemma: Evaluating your Aseptic Fill/Finish Manufacturing Strategy
Every biopharma company is eventually faced with the “make versus buy” decision – should they do the fill/finish manufacturing of their drug product in-house or
New manufacturing strategies for the precision medicine future
Blockbuster drugs and one-size-fits-all treatments now share portfolio space with highly targeted therapies for smaller patient populations. This new era is an opportunity for savvy